Patents Assigned to Sunnylife Pharma, Inc.
  • Tetrahydro-azepinoquinolines as agonists of the 5-HTreceptor
    Patent number: 10131660
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 20, 2018
    Assignee: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu
  • TETRAHYDRO-AZEPINOQUINOLINES AS AGONISTS OF THE 5-HT2C RECEPTOR
    Publication number: 20180215752
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Application
    Filed: August 26, 2015
    Publication date: August 2, 2018
    Applicant: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu